张国君

研究领域（200~300字介绍）：

从事分子影像学和乳腺癌的基础及临床研究。在分子影像方面：国内首创应用自主研发的光学分子影像手术导航系统进行乳腺癌前哨淋巴结活检和手术切缘判定，同时致力于研究多模态分子影像技术应用于恶性肿瘤的外科手术导航，特别是乳腺癌前哨淋巴结活检和外科手术切缘判定；建立基于创新药物为靶点的多模态分子影像平台并应用于抗癌药物疗效评价体系。在乳腺癌基础研究方面，阐明Notch3抑制乳腺癌发生、进展与转移的分子生物学机制。

学习经历（高等教育经历<本、硕、博>均需完整）

1981~1987中国医科大学日语医学专业 医学学士；

1990~1995中国医科大学普通外科学专业 医学博士；

1995~1999福岛县立医科大学外科肿瘤学专业 Ph.D.；

工作经历（需完整、连续，本校职称晋升过程要完整，博士后经历也需填写）

1987~1992中国医科大学第一临床学院 住院医师、总住院医师；

1992~1993中国医科大学第一临床学院 讲师、主治医师；

1993~1995日本国立癌中心医院 海外研究员；

1999~2004美国休斯医学研究所 博士后研究员；

2005~2008美国默克研究实验室 高级研究员

2008~2017汕头大学医学院附属肿瘤医院 院长

2017~ 厦门大学附属翔安医院 执行院长

代表性成果：

1. Lin H-Y, Liang Y-K, Dou X-W, Chen C-F, Wei X-L, Zeng D, Bai J-W, Guo Y-X, Lin F-F, Huang W-H, Du C-W, Li Y-C, Chen M,Zhang G-J. Notch3 inhibits epithelial–mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018;7(8):59.

2. Wen XF, Chen M, Wu Y, Chen MN, Glogowska A, Klonisch T,Zhang GJ. Inhibitor of DNA Binding 2 Inhibits Epithelial-Mesenchymal Transition via Up-Regulation of Notch3 in Breast Cancer. Translational oncology. 2018;11(5):1259-1270.

3. Zeng HC, Hu JL, Bai JW,Zhang GJ. Detection of Sentinel Lymph Nodes with Near-Infrared Imaging in Malignancies. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2018.

4. Dou XW, Liang YK, Lin HY, Wei XL, Zhang YQ, Bai JW, Chen CF, Chen M, Du CW, Li YC, Tian J, Man K,Zhang GJ. Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-alpha. Theranostics. 2017;7(16):4041-4056.

5. Bai J, Li Y,Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer biology & medicine. 2017;14(4):348-362.

6. J-W Bai, M-N Chen ,X-L Wei ,Y-Ch Li, H-Y Lin ,M Chen, J-W Li, C-W Du, K Man,Zhang GJ.The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer. Oncogenesis, 2017,6, e330.

7. He K, Chi C, Kou D, Huang W, Wu J, Wang Y, He L, Ye J, Mao Y,Zhang GJ^#, Wang J^#, Tian J^#. Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals. Transl Res, 2016, 178:74-80.

8. Zhang XX, Liu X, Luo J, Xiao W, Ye X, Chen M, Li YC^#,Zhang GJ^#. Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis, 2016, 5(11):e269.

9. Liang YK, Zeng D, Xiao YS, Wu Y, Ouyang YX, Chen M, Li YC, Lin HY, Wei XL, Zhang YQ, Kruyt FA^#,Zhang GJ^#. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Cancer Lett, 2016, 386:65-76.

10.Chen CF, Dou XW, Liang YK, Lin HY, Bai JW, Zhang XX, Wei XL, Yao-Chen L,Zhang GJ^#. Notch3 overexpression causes arrest of cell cycle progression by inducing Cdh1 expression in human breast cancer cells. Cell Cycle, 2016, 15(3):432-440.

11.Fu XJ, Shi XJ, Lin K, Lin H, Huang WH,Zhang GJ^#, Au WW^#. Environmental and DNA repair risk factors for breast cancer in South China. International Journal of Hygiene and Environmental Health, 2015, 218(3):313-8.

12.Wei XL, Zhang DH^#, Dou XW, Niu N, Bai JW, Huang WH andZhang GJ^#. Elevated 14, 15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer, 2014, 14:841.

13.Huang WH, Qiu SQ, Wu JD, Du CW, Cui YK andZhang GJ^#. Analysis of Clinicopathological Characteristics and Prognosis of 1425 Primary Breast Cancer Patients in Eastern Guangdong, China. Current Signal Transduction Therapy, 2014, 9(1):44-49.

14.Yang P, Liang SX, Huang WH, Zhang HW, Li XL, Xie LH, Du CW,Zhang GJ^#. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer. Current Molecular Medicine. 2014, 14(1):174-84.

15.Chi CW, Ye JZ, Ding HL, He D, Huang WH,Zhang GJ^#, Tian J^#. Use of Indocyanine Green for Detecting the Sentinel Lymph Node in Breast Cancer Patients: From Preclinical Evaluation to Clinical Validation. PLoS one, 2013, 8(12): e83927.

16.Xu HW, Huang YJ, Xie ZY, Lin L, Guo YC, Zhuang ZR, Lin XP, Zhou W, Mu L, Huang HH, Wei XL, Man K andZhang GJ^#. The expression of cytoglobin as a prognostic factor in gliomas:a retrospective analysis of 88 patients. BMC Cancer, 2013, 13:247.

17.Chen M, Cui YK, Huang WH, Man K andZhang GJ^#. Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen, Oncology Letters, 2013, 6(1):118-124.

18.Chen HW, Du CW, Wei XL, Khoo US,Zhang GJ^#. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancers. Current Molecular Medicine, 2013, 13(3):410-6.

19.Zhang GJ, Chen TB, Joseph D, Tao WK, Vanko A, Connolly B, David L. Williams J, Cyrille S. Visualization of Mitotic Arrest of Cell Cycle with Bioluminescence Imaging in Living Animals. Molecular Imaging and Biology, 2013, 15(4):431-40.

20.Zhang GJ, Chen TB, Connolly B, Lin SA, Hargreaves R, Vanko A, Bednar B, MacNeil DJ, Sur C, and Williams DL. In vivo optical imaging of LacZ expression using lacZ transgenic mice. Assay and Drug Development Technologies, 2009, 7(4):391-9.

21.Zhang GJ, Chen TB, Hargreaves R, Sur C, Williams Jr DL. Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways. Nature Protocols, 2008, 3(5):891-9.

22.Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, Williams Jr DL. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation. Neoplasia, 2007, 9(8):652-61.

23.Bednar B,Zhang GJ, Williams DL, Hargreaves R, Cyrille S. Optical imaging in drug discovery. Expert Opinion on Drug Discovery. 2007, 2(1):65-85.

24.Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T,Zhang GJ, Kondo K, Nose V, Kaelin Jr WG. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. American Journal of Pathology, 2006, 168(2):367-9.

25.Zhang GJ, Kaelin Jr WG. Bioluminescent Imaging of Ubiquitin Ligase Activity: Measuring Cdk2 Activity in vivo Through Changes in p27 Turnover. Methods in Enzymology. 2005, 399:530-49.

26.Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Shapiro G, Zhelev N, Kaelin Jr WG. Bioluminescent imaging of CDK2 inhibition in vivo. Nature Medicine, 2004, 10:643-8.

27.Olenyuk BZ,Zhang GJ, Klco JM, Nickols NG, Kaelin Jr WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(48):16768-73.

28.Wei W, Ayad NG, Wan Y,Zhang GJ, MW Kirschcner, Kaelin Jr WG. APCCDH1 targets SKP2 for ubiquitination and degradation. Nature, 2004, 428: 194-8.

29.Zhang GJ, Kimijima I, Fukushima T, Sato H, Kanno M, Tsuchiya A, Abe R. Tamoxifen induced apoptosis in breast cancer cells correlate to down-regulation of bcl-2 but not bcl-XL and bax, without alteration of p53 levels. Clinical Cancer Research, 1999, 5(10):2971-7.

30.Zhang GJ, Adachi I. Serum levels of soluble intercellular adhesion amolecule-1 and E-Selectin in metastatic breast carcinomas: correlations with Clinicopathological features and prognosis. International Journal of Oncology, 1999, 14(1):71-7.

31.Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Research, 1999, 19(2B): 1427-32.

32.Nakamura I, Kimijima I,Zhang GJ, Onogi H, Endo Y, Suzuki S, Tsuchiya A, Takenoshita S, Kusakabe T, Suzuki T. Fatty acid synthase expression in Japanese breast carcinoma patients. International Journal of Molecular Medicine, 1999, 4: 381-7.

33.Tshuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. Journal of Surgical Oncology, 1999, 70:230-4.

34.Tsuchiya A, Kanno M, Kawaguchi T, Endo Y,Zhang GJ,Ohtake T, Kimijima. Prognostic Relevance of Tn Expression in Breast Cancer. Breast Cancer, 1999, 6(3):175-80.

35.Tsuchiya A, Kanno M,Zhang GJ, Sagara H, Watanabe T, Kimijima I. Predicting Axillary Lymph Node Metastases in Breast Cancer Patients with Tumors under 2 cm in Size. Breast Cancer, 1999, 6(2):167-70.

36.Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Research, 1998, 18(3): 1989-98.

37.Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (Review). Oncology Reports, 1998,5(5):1211-6.

38.Zhang GJ, Kimijima I, Abe R, Kanno M, Katagata N, Hara K, Watanabe T, and Tsuchiya A. Correlation between the Expression of Apoptosis-related bcl-2 and p53 Oncoproteins and the Carcinogenesis and Progression of Breast Carcinomas. Clinical Cancer Research, 1997, 3 (12):2329-35.

39.Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Japanese Journal of Clinical Oncology, 1997, 27:371-7.

40.Zhang GJ, Adachi I, Duan Z, Zhang Q, Guo R, Tang L, Gong C, He S. Accuracy of color Doppler flow imaging for the detection of symptomatic deep venous thrombosis in Chinese patients. Surgery Today (Japanese Journal of Surgery), 1996, 26:683-7.

41.Zhang GJ, Adachi I, Yin DF, Narabayashi M, Tokue Y, Watanabe T, Kaneko A, Tsuda H, and Abe K. Eyelid Metastasis from breast cancer showing marked response to chemotherapy. Japanese Journal of Clinical Oncology, 1995, 25(1): 10-5.

42.Zhang GJ, Adachi I, Okamoto R, Watanabe T, Narabayashi M, Tokue Y, and Katsumata M. Tumor-associated fever in recurrent breast cancer with liver metastases. Breast Cancer, 1994, 1(2): 145-50.

主持过的重要课题：

1. 中国人社部百千万工程领军人才，2016,60万元,肿瘤学

2. 广东省自然科学基金研究团队，2016A030312008，基于多模态分子影像技术的乳腺癌精准医疗，2016/06-2021/06，300万元，在研，主持

3. “广东特支计划”杰出人才（南粤百杰），2015，分子影像学

4. 国家自然科学基金重大国际(地区)合作研究项目，81320108015，光学分子成像技术监测Notch3信号通路介导的乳腺癌的上皮间质转，2014/01-2018/12，280万元，在研，主持

5. 汕头大学医学院临床提升计划，201420，ICG法与美蓝法检测乳腺癌前哨淋巴结的多中心前瞻性随机对照研究，2014/06-2017/06，60万元，已结题，主持

6. 国家自然科学基金面上项目，31271068，光学分子影像技术在活体小动物示踪细胞周期的实验研究，2013/01-2016/12，80万元，已结题，主持

7. 教育部高校博士学科点专项科研基金，20124402110003，光学分子影像技术在活体小动物示踪细胞周期的实验研究，2013/01-2015/12，12万元，已结题，主持

8. 广东省实验室体系建设专项资金项目，2060299，广东省乳腺癌诊治研究重点实验室，2012/10-2015/09，200万，已结题，主持

9. 长江学者（特聘教授），2012年，分子影像学

10.国家重点基础研究发展计划（973），2011CB707705，多模态分子影像在乳腺癌早期精确诊断和抗肿瘤药物疗效评价中的应用，2011/01-2015/08，450万元，已结题，主持

11.广东省自然科学基金项目，10351503102000000，应用生物发光分子影像研究三阴性乳腺癌侵袭转移的分子生物学机制，2010/01-2012/12，5万元，已结题，主持

12.国家自然科学基金面上项目，30973377，构建在活体小动物示踪有丝分裂调控的光学分子影像报告基因的实验研究，2010/01-2012/12，34万元，已结题，主持

13.广东省科技计划项目，2009B050200013，CXCR4和L-SIGN对人三阴性乳腺癌进展与转移作用的研究，2009/10-2012/10，20万元，已结题，主持

已申请的专利：

1. 张国君，赵瑞君，陈志鸿，细胞周期S期报告基因，2014/1/8，中国，ZL201110075260.1

备注：

1. 字体：姓名：方正小标宋小二号、加粗；

其他：仿宋四号；

英语和数字请用Time New Roman字体

2.填写时范例请删除；

3.照片请尽量选用正面证件照，480*640